Survival outcomes after adjuvant radiation in women ≥ 65 years diagnosed with ductal carcinoma in-situ: Analysis of National Cancer Data Base.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 1058-1058
Author(s):  
Wenli Gao ◽  
Prakash Peddi ◽  
Gary Von Burton ◽  
Runhua Shi
2016 ◽  
Vol 23 (10) ◽  
pp. 3337-3346 ◽  
Author(s):  
Megan E. Miller ◽  
Alexandra Kyrillos ◽  
Katharine Yao ◽  
Olga Kantor ◽  
Jennifer Tseng ◽  
...  

The Breast ◽  
2019 ◽  
Vol 43 ◽  
pp. 55-58
Author(s):  
Won Kyung Cho ◽  
Doo Ho Choi ◽  
Haeyoung Kim ◽  
Jae Myoung Noh ◽  
Won Park ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6040-6040
Author(s):  
Tomasz Czechura ◽  
Katharine Yao ◽  
Dezheng Huo ◽  
Arif Shaikh ◽  
David Porter Winchester ◽  
...  

6040 Background: The use of accelerated partial breast irradiation using brachytherapy (APBI-b) for patients with invasive cancer is increasing but data for ductal carcinoma in situ (DCIS) cases are limited. The American Society of Radiation Oncology (ASTRO) guidelines suggest that APBI-b should be used only on a "cautionary" or "on trial" basis for women with DCIS. The purpose of this study was to examine utilization trends and correlates of APBI-b use for patients with DCIS. Methods: A total of 70,043 postlumpectomy patients from the National Cancer Database diagnosed with DCIS between 2002 and 2007 were studied. Chi-square tests and logistic regression models were used to determine trends and factors related to APBI-b use. Results: The use of APBI-b increased from 0.7% in 2002 to 10.0% in 2007 (p<0.001). Independent predictors APBI-b use were age, race, insurance status, comorbidity index, facility type, and facility location. Older patients were more likely to use APBI-b; relative to patients 30-39 years old, the OR for patients 80-89 years old was 5.9 (95% CI: 3.7-9.6). APBI-b use was higher in whites (4.9%), compared to blacks (4.4%), Hispanics (2.8%), and Asian pacific islanders (1.5%; p<0.001). Compared to noninsured, Medicare (OR=2.1, 95% CI: 1.3-3.3) and managed care patients (OR=2.0, 95% CI: 1.3-3.2) were more likely to undergo APBI-b. 2.3% of community cancer programs, 5.7% of comprehensive community programs and 4.1% of academic/research programs utilized APBI-b for treating DCIS (p<0.001). The use of APBI-b varied significantly by facility location; the West and South regions of the country were more likely to use APBI-b (OR=14, 95% CI: 10.1-19.6) than the Northeast region. 91% of the APBI-b patients fit the ASTRO "cautionary" guideline and 9% of patients fit the ASTRO "on trial" guidelines. In 2002, 4% of ABPI-b patients fit the "on trial" guidelines which increased to 8.6% in 2007 (p<0.001). Conclusions: The use of APBI-b for DCIS increased from 2002-2007. APBI-b use varies by socioeconomic and facility factors with age being the most significant factor. Future studies are needed to determine the indications for APBI-b in patients with DCIS.


2009 ◽  
Vol 27 (19) ◽  
pp. 3211-3216 ◽  
Author(s):  
Larissa Nekhlyudov ◽  
Laurel A. Habel ◽  
Ninah S. Achacoso ◽  
Inkyung Jung ◽  
Reina Haque ◽  
...  

Purpose Breast-conserving surgery (BCS) is an effective treatment for ductal carcinoma in situ (DCIS) but women who undergo BCS remain at risk for recurrences. Whether mammographic surveillance after BCS occurs and by whom is not known. Methods We reviewed medical records of women diagnosed with DCIS between 1990 and 2001 and treated with BCS. Using descriptive statistics, generalized estimating, and logistic regression modeling, we examined the rates and predictors of surveillance mammography over a 10-year period after BCS. Results The cohort included 3,037 women observed for a median of 4.8 years (range, 0.5 to 15.7). Of the 2,676 women observed for at least 1 year after BCS, most (79%) had at least one surveillance mammogram during the first year of follow-up; 69% in year 5 and 61% in year 10. Among those observed for 5 years, surveillance mammograms were more likely among women age 60 to 69 years (odds ratio [OR], 1.72; 95% CI, 1.26 to 2.34), users of menopausal hormone therapy at diagnosis (OR, 1.26; 95% CI, 1.01 to 1.57) as well as those treated with adjuvant radiation (OR, 1.28; 95% CI, 1.08 to 1.53) and adjuvant radiation with tamoxifen (OR, 1.61; 95% CI, 1.13 to 2.30). Surveillance mammograms were less likely among obese women (OR, 0.70; 95% CI, 0.56 to 0.86). The findings were similar among women observed for 10 years. Only 34% and 15% of women observed for 5 and 10 years, respectively, had a surveillance mammogram during each year of follow-up. Conclusion Surveillance mammography after BCS among insured women with DCIS often did not occur yearly and declined over time after treatment. Patients and providers must remain vigilant about surveillance after BCS.


2021 ◽  
Vol 33 (1) ◽  
pp. 40-45
Author(s):  
M. Co ◽  
R.K.C. Ngan ◽  
O.W.K. Mang ◽  
A.H.P. Tam ◽  
K.H. Wong ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document